Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C22H25NO3 |
| Molecular Weight | 351.4388 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1OC(CCN2CCCCC2)OC1(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=DXSUDONPFZKWOO-UHFFFAOYSA-N
InChI=1S/C22H25NO3/c24-21-22(18-10-4-1-5-11-18,19-12-6-2-7-13-19)26-20(25-21)14-17-23-15-8-3-9-16-23/h1-2,4-7,10-13,20H,3,8-9,14-17H2
Pipoxolan is an antispasmodic drug. In vivo, the drug inhibited the contractions of intestines caused by neostigmine, barium chloride or injection of acetylcholine. The drug possesses ganglioplegic action and inhibited the decrease in blood pressure caused by stimulation of the vagus nerve. The drug is marketed under tradename Rowapraxin worldwide for the treatment of spasms and colics in the gastrointestinal tract, gallbladder and urogenital area, bronchial spasms, spastic menstrual cramps. Recent studies have shown that pipoxalan has anticancer activity and inhibits proliferation of leukemia cells in animal models.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB09881MIG
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
2862
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
33758
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | RxNorm | ||
|
2194
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
25100-40-7
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
SUPERSEDED | |||
|
100000082197
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
DTXSID20865113
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
C000121
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
28932
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110645
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
27769-60-4
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
SUPERSEDED | |||
|
23744-24-3
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
493GZJ5T6I
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
C166739
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
